O. S. Donirova
Research Subjects
O. S. Donirova has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- A. Ya. Kovaleva
Institute of Chemical Biology and Fundamental Medicine
3 shared publications - Elena M Zelenskaya
Institute of Chemical Biology and Fundamental Medicine
3 shared publications - Elena Nikolaevna Voronina
Knorre Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia
3 shared publications - Galina Israilevna Lifshits
Institute of Chemical Biology and Fundamental Medicine
3 shared publications - Konstantin Viktorovich Protasov
Irkutsk State Medical Academy of Postgraduate Education Branch of Russian Medical Academy of Continuing Professional Education
3 shared publications - Natalia Viktorovna Kokh
Novosibirsk National Research State University
2 shared publications
Latest Publications
- Open Access
- 11 November 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (9) , 4609
Current hypertension treatment possibilities and tactics in patients with comorbidities. The role of selective imidazoline receptor agonists. Expert opinion
Hypertension (HTN) is a serious public health problem. Despite advances in diagnosis and public awareness, the percentage of controlled cases remains low, especially among men and the elderly. The main challenges are related to comorbidities such as obesity, diabetes, chronic kidney disease, and obstructive sleep apnea, which worsen the prognosis and increase the risk of cardiovascular events. The approach to HTN treatment should be individualized and take into account specific disease phenotypes and comorbidities. It is important to identify patients with increased sympathetic nervous system activity, as this group experiences the greatest difficulties in blood pressure control. Moxonidine, a centrally acting agent, selectively stimulates imidazoline receptors in the brain, causing a decrease in sympathetic activity and effective reduction in blood pressure. The need for a personalized approach to HTN therapy is driven by the growing number of patients with multiple comorbidities and complex pathogenesis. New approaches, including early initiation of combination therapy and targeted management of metabolic risk factors, will reduce cardiovascular morbidity and mortality. Moxonidine plays a key role within antihypertensive medications due to its unique mechanism of action and ability to positively impact a wide range of HTN-related pathologies
- 11 November 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (9) , 4609
Open AccessCurrent hypertension treatment possibilities and tactics in patients with comorbidities. The role of selective imidazoline receptor agonists. Expert opinion
Hypertension (HTN) is a serious public health problem. Despite advances in diagnosis and public awareness, the percentage of controlled cases remains low, especially among men and the elderly. The main challenges are related to comorbidities such as obesity, diabetes, chronic kidney disease, and obstructive sleep apnea, which worsen the prognosis and increase the risk of cardiovascular events. The approach to HTN treatment should be individualized and take into account specific disease phenotypes and comorbidities. It is important to identify patients with increased sympathetic nervous system activity, as this group experiences the greatest difficulties in blood pressure control. Moxonidine, a centrally acting agent, selectively stimulates imidazoline receptors in the brain, causing a decrease in sympathetic activity and effective reduction in blood pressure. The need for a personalized approach to HTN therapy is driven by the growing number of patients with multiple comorbidities and complex pathogenesis. New approaches, including early initiation of combination therapy and targeted management of metabolic risk factors, will reduce cardiovascular morbidity and mortality. Moxonidine plays a key role within antihypertensive medications due to its unique mechanism of action and ability to positively impact a wide range of HTN-related pathologies
- 14 April 2025
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 20 (1)
Characteristics, treatment features and in-hospital mortality of patients with myocardial infarction over 75 years old in Russia according to the REGION-IM registry
Despite widespread elderly population, these patients are underrepresented in clinical trials. Considering the Russian prospective registry REGION-IM, the authors analyzed anamnestic, demographic and clinical characteristics of patients with acute MI over ≥ 75 years old, treatment features and in-hospital mortality. The results were compared with the data of Russian and foreign ACS registries. Patients with MI ≥75 years old in the Russian Federation are characterized by severe comorbidities, less frequent invasive treatment and prescription of necessary drugs. Elderly patients have longer patient-associated reperfusion delay, symptom-to-diagnosis and symptom-to-hospitalization time, which may be explained by atypical symptoms, mental problems and social factors. In-hospital mortality is much higher in patients ≥75 years old. Elderly patients with MI represent a high-risk group that dictates the need for active and balanced approach at all stages of treatment.
- 14 April 2025
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 20 (1)
Characteristics, treatment features and in-hospital mortality of patients with myocardial infarction over 75 years old in Russia according to the REGION-IM registry
Despite widespread elderly population, these patients are underrepresented in clinical trials. Considering the Russian prospective registry REGION-IM, the authors analyzed anamnestic, demographic and clinical characteristics of patients with acute MI over ≥ 75 years old, treatment features and in-hospital mortality. The results were compared with the data of Russian and foreign ACS registries. Patients with MI ≥75 years old in the Russian Federation are characterized by severe comorbidities, less frequent invasive treatment and prescription of necessary drugs. Elderly patients have longer patient-associated reperfusion delay, symptom-to-diagnosis and symptom-to-hospitalization time, which may be explained by atypical symptoms, mental problems and social factors. In-hospital mortality is much higher in patients ≥75 years old. Elderly patients with MI represent a high-risk group that dictates the need for active and balanced approach at all stages of treatment.
- Open Access
- 7 July 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 28 (10) , 5504
Predictors of angina pain relapse after coronary stenting for acute coronary syndrome in Buryats
Aim. To identify and rank factors predisposing to angina relapse in Buryat patients who underwent percutaneous intervention for acute coronary syndrome.Material and methods. The study included 142 Buryat patients who underwent coronary stenting for acute coronary syndrome. All patients received clopidogrel. The CYP2C19*2 and CYP2C19*3 alleles were determined. Efficacy endpoints were assessed according to the Academic Research Consortium-2 criteria. Laboratory parameters and concomitant omeprazole therapy were assessed.Results. This study examined in detail a group of patients with short-term angina relapse without formal signs of unstable angina. A logistic regression model was obtained that makes it possible to identify and rank independent risk factors for recurrent angina in Buryat patients. Risk factors were ranked as follows: carriage of CYP2C19*2 and/or CYP2C19*3 alleles (coefficient b1=3,489, 95% confidence interval (CI) (3,096-346,213)), treatment with omeprazole (b2=2,816, 95% CI (2,745-101,616)), male sex (b3=2,749, 95% CI (1,425-163,458)) and blood glucose level (b4=0,354, 95% CI (1,141-1,779)).Conclusion. Thus, angina pain relapse in Buryat patients is facilitated by signs significant for recurrent myocardial infarction. This study suggests that patients with recurrent angina pain without electrocardiographic deterioration and biomarker elevation may require more careful personalization of therapy.
- 7 July 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 28 (10) , 5504
Open AccessPredictors of angina pain relapse after coronary stenting for acute coronary syndrome in Buryats
Aim. To identify and rank factors predisposing to angina relapse in Buryat patients who underwent percutaneous intervention for acute coronary syndrome.Material and methods. The study included 142 Buryat patients who underwent coronary stenting for acute coronary syndrome. All patients received clopidogrel. The CYP2C19*2 and CYP2C19*3 alleles were determined. Efficacy endpoints were assessed according to the Academic Research Consortium-2 criteria. Laboratory parameters and concomitant omeprazole therapy were assessed.Results. This study examined in detail a group of patients with short-term angina relapse without formal signs of unstable angina. A logistic regression model was obtained that makes it possible to identify and rank independent risk factors for recurrent angina in Buryat patients. Risk factors were ranked as follows: carriage of CYP2C19*2 and/or CYP2C19*3 alleles (coefficient b1=3,489, 95% confidence interval (CI) (3,096-346,213)), treatment with omeprazole (b2=2,816, 95% CI (2,745-101,616)), male sex (b3=2,749, 95% CI (1,425-163,458)) and blood glucose level (b4=0,354, 95% CI (1,141-1,779)).Conclusion. Thus, angina pain relapse in Buryat patients is facilitated by signs significant for recurrent myocardial infarction. This study suggests that patients with recurrent angina pain without electrocardiographic deterioration and biomarker elevation may require more careful personalization of therapy.
- Open Access
- 13 October 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (12) , 4642
Cystatin C-based estimated glomerular filtration rate after percutaneous coronary intervention in the prediction of inhospital mortality in acute myocardial infarction
Aim. To assess the significance of changes cystatin C-based estimated glomerular filtration rate (eGFRcys) in predicting inhospital mortality in patients with acute ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).Material and methods. In 133 patients with STEMI, serum creatinine and cystatin C were determined. Creatinine clearance (CrCl) was estimated according to Cockcroft-Gault equation. Creatinine-based estimated glomerular filtration rate (eGFRcr) was assessed using the MDRD (eGFRcr_MDRD) and CKD-EPI 2009 (eGFRcr_CKD-EPI). In addition, eGFRcys and a combination of serum creatinine and cystatin C (eGFRcr-cys) was assessed using the CKD-EPI 2012 equation at admission and 24-48 hours after PCI. In the groups of deceased patients and survivors, the studied parameters were compared. Their relationship with imhospital mortality was assessed by logistic regression adjusted for acute kidney injury (AKI) and GRACE risk. To assess the informativeness of identified independent predictors, an ROC analysis was performed.Results. After PCI, serum creatinine level increased by 9,8%, cystatin C — by 38,2%. CrCl decreased by 9,0%, eGFRcr_MDRD — by 10,2%, eGFRcr_CKD-EPI — by 5,2%, eGFRcys — by 29,5%, eGFRcr-cys — by 19,3%. AKI was diagnosed in 21 people (15,8%). Among the deceased patients (n=12), compared with the survivors, serum creatinine level was higher at baseline and after PCI, cystatin C — after PCI, eGFR of any calculation method was lower, while AKI developed more often. According to multivariate regression analysis, the eGFRcr-cys after PCI and the GRACE risk score were independent predictors of the endpoint. The area under the ROC curve for eGFRcr-cys after PCI was 0,835 [0,712-0,958], while the cut-off point was 38 ml/min/1,73 m2, below which the odds ratio of developing a fatal outcome was 22,2 with a 95% confidence interval of 5,7- 86,8.Conclusion. Estimated GFR determined 24-48 h after PCI based on the combination of serum creatinine and cystatin C using the CKD-EPI 2012 equation was an independent predictor of inhospital mortality in STEMI. The cut-off point of this parameter was 38 ml/min/1,73 m2, below which the death risk increases significantly. The results indicate the viability of introducing novel methods for assessing renal function based on cystatin C to improve the quality of prediction in STEMI.
- 13 October 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (12) , 4642
Open AccessCystatin C-based estimated glomerular filtration rate after percutaneous coronary intervention in the prediction of inhospital mortality in acute myocardial infarction
Aim. To assess the significance of changes cystatin C-based estimated glomerular filtration rate (eGFRcys) in predicting inhospital mortality in patients with acute ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).Material and methods. In 133 patients with STEMI, serum creatinine and cystatin C were determined. Creatinine clearance (CrCl) was estimated according to Cockcroft-Gault equation. Creatinine-based estimated glomerular filtration rate (eGFRcr) was assessed using the MDRD (eGFRcr_MDRD) and CKD-EPI 2009 (eGFRcr_CKD-EPI). In addition, eGFRcys and a combination of serum creatinine and cystatin C (eGFRcr-cys) was assessed using the CKD-EPI 2012 equation at admission and 24-48 hours after PCI. In the groups of deceased patients and survivors, the studied parameters were compared. Their relationship with imhospital mortality was assessed by logistic regression adjusted for acute kidney injury (AKI) and GRACE risk. To assess the informativeness of identified independent predictors, an ROC analysis was performed.Results. After PCI, serum creatinine level increased by 9,8%, cystatin C — by 38,2%. CrCl decreased by 9,0%, eGFRcr_MDRD — by 10,2%, eGFRcr_CKD-EPI — by 5,2%, eGFRcys — by 29,5%, eGFRcr-cys — by 19,3%. AKI was diagnosed in 21 people (15,8%). Among the deceased patients (n=12), compared with the survivors, serum creatinine level was higher at baseline and after PCI, cystatin C — after PCI, eGFR of any calculation method was lower, while AKI developed more often. According to multivariate regression analysis, the eGFRcr-cys after PCI and the GRACE risk score were independent predictors of the endpoint. The area under the ROC curve for eGFRcr-cys after PCI was 0,835 [0,712-0,958], while the cut-off point was 38 ml/min/1,73 m2, below which the odds ratio of developing a fatal outcome was 22,2 with a 95% confidence interval of 5,7- 86,8.Conclusion. Estimated GFR determined 24-48 h after PCI based on the combination of serum creatinine and cystatin C using the CKD-EPI 2012 equation was an independent predictor of inhospital mortality in STEMI. The cut-off point of this parameter was 38 ml/min/1,73 m2, below which the death risk increases significantly. The results indicate the viability of introducing novel methods for assessing renal function based on cystatin C to improve the quality of prediction in STEMI.
- Open Access
- 22 May 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (4) , 4308
Role of soluble ST2 in short-term prediction of acute heart failure in acute ST-elevation myocardial infarction
Aim. To investigate the relationship of soluble ST2 (sST2) to acute heart failure (AHF) and compare the predictive value of sST2 and brain natriuretic peptide in patients with ST-elevation myocardial infarction (STEMI).Material and methods. In 136 STEMI patients, the serum sST2 concentration was determined during the first 24 hours of hospitalization. We assessed levels of sST2, N-terminal pro-brain natriuretic peptide (NT-proBNP), incidence of Killip class II-IV AHF during hospitalization, myocardial necrosis biomarkers, parameters of complete blood count and biochemical blood tests, the incidence of cardiovascular diseases and risk factors. The predictive value of sST2 for AHF development was assessed using logistic regression. ROC analysis was performed. The areas under the ROC curve were compared for sST2 and NT-proBNP. The cut-off sST2 value was determined for predicting AHF.Results. The mean sST2 level was 43,4 (33,6-73,9) ng/ml. During the followup period, AHF was diagnosed in 54 people (39,7%). The prevalence of AHF in the 1st, 2ndand 3rd tertiles of sST2 was 15,6%, 33,3% and 69,7%, respectively. The NT-proBNP levels were 319 (128-1072) pg/ml, 430 (147-1140) pg/ml and 1317 (533-2386) pg/ml. The predictive value of 3rdsST2 tertile was retained adjusted for age, sex, NT-proBNP, troponin T, creatine phosphokinase-MB, high-sensitivity C-reactive protein, hemoglobin, blood glucose, left ventricular ejection fraction. The areas under the ROC curves for sST2 and NT-proBNP were comparable (0,828 and 0,733, respectively; p=0,056). The cut-off sST2 value was 64 ng/ml, above which the odds ratio of AHF was 11,1 (95% confidence interval, 4,7-26,1.Conclusion. An increase in blood sST2 is associated with an increase in AHF (Killip II-IV) prevalence in hospitalized patients with acute STEMI. Soluble ST2 has an independent predictive value for AHF in STEMI, comparable in strength and predictive model quality to NT-proBNP. The cut-off sST2 value for AHF (>64 ng/ ml) was calculated, which provides an optimal balance of sensitivity, specificity and accuracy of the prognostic model. These data support the potential value of sST2 as a biomarker of AHF in STEMI.
- 22 May 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (4) , 4308
Open AccessRole of soluble ST2 in short-term prediction of acute heart failure in acute ST-elevation myocardial infarction
Aim. To investigate the relationship of soluble ST2 (sST2) to acute heart failure (AHF) and compare the predictive value of sST2 and brain natriuretic peptide in patients with ST-elevation myocardial infarction (STEMI).Material and methods. In 136 STEMI patients, the serum sST2 concentration was determined during the first 24 hours of hospitalization. We assessed levels of sST2, N-terminal pro-brain natriuretic peptide (NT-proBNP), incidence of Killip class II-IV AHF during hospitalization, myocardial necrosis biomarkers, parameters of complete blood count and biochemical blood tests, the incidence of cardiovascular diseases and risk factors. The predictive value of sST2 for AHF development was assessed using logistic regression. ROC analysis was performed. The areas under the ROC curve were compared for sST2 and NT-proBNP. The cut-off sST2 value was determined for predicting AHF.Results. The mean sST2 level was 43,4 (33,6-73,9) ng/ml. During the followup period, AHF was diagnosed in 54 people (39,7%). The prevalence of AHF in the 1st, 2ndand 3rd tertiles of sST2 was 15,6%, 33,3% and 69,7%, respectively. The NT-proBNP levels were 319 (128-1072) pg/ml, 430 (147-1140) pg/ml and 1317 (533-2386) pg/ml. The predictive value of 3rdsST2 tertile was retained adjusted for age, sex, NT-proBNP, troponin T, creatine phosphokinase-MB, high-sensitivity C-reactive protein, hemoglobin, blood glucose, left ventricular ejection fraction. The areas under the ROC curves for sST2 and NT-proBNP were comparable (0,828 and 0,733, respectively; p=0,056). The cut-off sST2 value was 64 ng/ml, above which the odds ratio of AHF was 11,1 (95% confidence interval, 4,7-26,1.Conclusion. An increase in blood sST2 is associated with an increase in AHF (Killip II-IV) prevalence in hospitalized patients with acute STEMI. Soluble ST2 has an independent predictive value for AHF in STEMI, comparable in strength and predictive model quality to NT-proBNP. The cut-off sST2 value for AHF (>64 ng/ ml) was calculated, which provides an optimal balance of sensitivity, specificity and accuracy of the prognostic model. These data support the potential value of sST2 as a biomarker of AHF in STEMI.
- Open Access
- 30 December 2020
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 24 (4) , 103-113
Identification of ethnogenetic differences in genetic markers in the clinical course and damage to target organs in arterial hypertension in Russians and Buryats
Аim. To study the influence of genetic factors on the severity of essential аrteriаl hypertension (AH) clinical outcomes in patients of Russian and Buryаt ethnicity.Methods. Our study included 206 patients with а diagnosis of essential AH: 136 patients were of Russiаn аnd 70 patients were of Buryаt ethnicity. Pаtients were evаluаted for the following genotype markers; АCE, АDRB1, АDRB2, АDRB3, NOS3, АGT, EDN1, GNB3, and STK39.Results. Allele T of GNB3 was аssociаted with high blood pressure in Russiаn аnd Buryаt patients. In Buryat patients, locus rs934379 of EDN1 was аssociаted with high blood pressure, whereas allele G of the same marker was associated with increased heart damage risk. In Russians, allele I of ACE was protective towards the development of left ventricular hypertrophy.Conclusion. Our data revealed ethnogenetic differences in the genetic features of essential AH. We identified the patients severe hypertension among two etnhic group. Studying ethnic genetic markers for essential AH facilitates a greater understanding of the genetic predisposition underlying this condition. Received 2 July 2020. Revised 31 August 2020. Accepted 9 September 2020. Funding: The work is supported by grant of the Russian Foundation for Basic Research (project No. 19-315-80032). Conflict of interest: Authors declare no conflict of interest. Author contributionsConception and design: N.V. Kokh, E.M. Zelenskаyа, G.I. LifshitsData collection and analysis: A.Yа. Kovаlevа, N.V. Kokh, E.N. Voroninа, O.S. Donirovа, E.M. Zelenskаyа, A.A. Slepukhina, G.I. LifshitsStatistical analysis: N.V. KokhDrafting the article: A.Yа. Kovаlevа, N.V. Kokh, E.N. Voroninа, O.S. Donirovа, E.M. Zelenskаyа, A.A. Slepukhina, G.I. LifshitsCritical revision of the article: A.Yа. Kovаlevа, N.V. Kokh, E.N. Voroninа, O.S. Donirovа, E.M. Zelenskаyа, A.A. Slepukhina, G.I. LifshitsFinal approval of the version to be published: A.Yа. Kovаlevа, N.V. Kokh, E.N. Voroninа, O.S. Donirovа, E.M. Zelenskаyа, A.A. Slepukhina, G.I. Lifshits
- 30 December 2020
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 24 (4) , 103-113
Open AccessIdentification of ethnogenetic differences in genetic markers in the clinical course and damage to target organs in arterial hypertension in Russians and Buryats
Аim. To study the influence of genetic factors on the severity of essential аrteriаl hypertension (AH) clinical outcomes in patients of Russian and Buryаt ethnicity.Methods. Our study included 206 patients with а diagnosis of essential AH: 136 patients were of Russiаn аnd 70 patients were of Buryаt ethnicity. Pаtients were evаluаted for the following genotype markers; АCE, АDRB1, АDRB2, АDRB3, NOS3, АGT, EDN1, GNB3, and STK39.Results. Allele T of GNB3 was аssociаted with high blood pressure in Russiаn аnd Buryаt patients. In Buryat patients, locus rs934379 of EDN1 was аssociаted with high blood pressure, whereas allele G of the same marker was associated with increased heart damage risk. In Russians, allele I of ACE was protective towards the development of left ventricular hypertrophy.Conclusion. Our data revealed ethnogenetic differences in the genetic features of essential AH. We identified the patients severe hypertension among two etnhic group. Studying ethnic genetic markers for essential AH facilitates a greater understanding of the genetic predisposition underlying this condition. Received 2 July 2020. Revised 31 August 2020. Accepted 9 September 2020. Funding: The work is supported by grant of the Russian Foundation for Basic Research (project No. 19-315-80032). Conflict of interest: Authors declare no conflict of interest. Author contributionsConception and design: N.V. Kokh, E.M. Zelenskаyа, G.I. LifshitsData collection and analysis: A.Yа. Kovаlevа, N.V. Kokh, E.N. Voroninа, O.S. Donirovа, E.M. Zelenskаyа, A.A. Slepukhina, G.I. LifshitsStatistical analysis: N.V. KokhDrafting the article: A.Yа. Kovаlevа, N.V. Kokh, E.N. Voroninа, O.S. Donirovа, E.M. Zelenskаyа, A.A. Slepukhina, G.I. LifshitsCritical revision of the article: A.Yа. Kovаlevа, N.V. Kokh, E.N. Voroninа, O.S. Donirovа, E.M. Zelenskаyа, A.A. Slepukhina, G.I. LifshitsFinal approval of the version to be published: A.Yа. Kovаlevа, N.V. Kokh, E.N. Voroninа, O.S. Donirovа, E.M. Zelenskаyа, A.A. Slepukhina, G.I. Lifshits
- Open Access
- 3 November 2019
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 10,p. 66-71
The relationship of genetic risk factors with the development of arterial hypertension taking into account ethnic differences
Связь генетических факторов риска с развитием артериальной гипертонии с учётом этнических различий
- 3 November 2019
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 10,p. 66-71
Open AccessThe relationship of genetic risk factors with the development of arterial hypertension taking into account ethnic differences
Связь генетических факторов риска с развитием артериальной гипертонии с учётом этнических различий